Deal Statistics Quarterly, Q2 2002
Executive Summary
In Vivo presents another installment of our quarterly review of dealmaking--in this case April through June 2002. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
You may also be interested in...
Stryker Expands in Spine with Surgical Dynamics
With so much interesting technology in the spine market today, valuations are sky high. Stryker's $135 million deal for Surgical Dynamics raises eyebrows for its low price. But if it isn't the boldest move in spine, Stryker's deal could very turn out to be a very good one, as the company gains an important foothold in the spinal cage market.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.